Progress in systemic therapy for advanced-stage urothelial carcinoma
Nature Reviews Clinical Oncology, Published online: 09 November 2023; doi:10.1038/s41571-023-00826-2Patients with advanced-stage urothelial cancer (aUC) continue to have poor long-term survival outcomes. However, developments in the past 5 years, most notably the availability of maintenance therapy with the anti-PD-1 antibody avelumab, are beginning to change this issue. In this Review, the authors provide an overview of the treatment of patients with aUC, including considerations of the various promising new therapeutic modalities and how they might improve clinical outcomes. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 9, 2023 Category: Cancer & Oncology Authors: Rosa Nadal Bego ña P. Valderrama Joaquim Bellmunt Source Type: research
From ESMO 2023: advances in lung cancer
Nature Reviews Clinical Oncology, Published online: 03 November 2023; doi:10.1038/s41571-023-00838-yFrom ESMO 2023: advances in lung cancer (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 3, 2023 Category: Cancer & Oncology Authors: Peter Sidaway Source Type: research
From CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC
Nature Reviews Clinical Oncology, Published online: 03 November 2023; doi:10.1038/s41571-023-00839-xFrom CHRYSALIS to PAPILLON: the metamorphosis of amivantamab into frontline therapy for NSCLC (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 3, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
Activity of selpercatinib confirmed in phase III trials
Nature Reviews Clinical Oncology, Published online: 02 November 2023; doi:10.1038/s41571-023-00837-zActivity of selpercatinib confirmed in phase III trials (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
THOR provides new data on the efficacy of erdafitinib
Nature Reviews Clinical Oncology, Published online: 02 November 2023; doi:10.1038/s41571-023-00836-0THOR provides new data on the efficacy of erdafitinib (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - November 2, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Computational immunogenomic approaches to predict response to cancer immunotherapies
Nature Reviews Clinical Oncology, Published online: 31 October 2023; doi:10.1038/s41571-023-00830-6Identifying patients who are likely to benefit from immune-checkpoint inhibitors remains one of the major challenges in immunotherapy. Cancer immunogenomics is an emerging field that bridges genomics and immunology. The authors of this Review provide an overview of the computational approaches currently available to analyse bulk tissue and single-cell sequencing data from cancer, stromal and immune cells. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 31, 2023 Category: Cancer & Oncology Authors: Venkateswar Addala Felicity Newell John V. Pearson Alec Redwood Bruce W. Robinson Jenette Creaney Nicola Waddell Source Type: research
From the ESMO Congress 2023
Nature Reviews Clinical Oncology, Published online: 31 October 2023; doi:10.1038/s41571-023-00835-1From the ESMO Congress 2023 (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 31, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
Nature Reviews Clinical Oncology, Published online: 30 October 2023; doi:10.1038/s41571-023-00832-4Despite some success in patients with certain B cell malignancies and relapsed and/or refractory multiple myeloma, studies testing chimeric antigen receptor (CAR) T cells in patients with advanced-stage solid tumours have been largely unsuccessful, with a few notable exceptions. In this Perspective, the author provides some possible reasons for the failures of most CAR T cell-based approaches and suggests strategies that might address some of these challenges. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 30, 2023 Category: Cancer & Oncology Authors: Steven M. Albelda Source Type: research
Global trends in hepatocellular carcinoma epidemiology: implications for screening, prevention and therapy
Nature Reviews Clinical Oncology, Published online: 26 October 2023; doi:10.1038/s41571-023-00825-3Hepatocellular carcinoma (HCC) is among the most common causes of cancer-related death globally, and despite improvements in prevention and treatment strategies, continued increases in HCC incidence and mortality are predicted. Cirrhosis remains the major risk factor for HCC, although the underlying aetiology is shifting from virus-related to non-viral liver diseases. In this Review, the authors discuss the changing trends in HCC epidemiology and their implications for screening, prevention and therapy, including opportunitie...
Source: Nature Reviews Clinical Oncology - October 26, 2023 Category: Cancer & Oncology Authors: Amit G. Singal Fasiha Kanwal Josep M. Llovet Source Type: research
Digital symptom assessment tools: the next frontier in financial toxicity screening
Nature Reviews Clinical Oncology, Published online: 25 October 2023; doi:10.1038/s41571-023-00833-3PRO-TECT is a randomized trial that innovatively integrated financial toxicity screening into a pre-existing digital symptom-monitoring programme, enabling longitudinal detection of financial toxicity. Such a strategy provides an unobtrusive and cost-effective method for early detection and mitigation of financial toxicity by aligning the needs of patients and carers with the resources available in community clinical practices. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 25, 2023 Category: Cancer & Oncology Authors: Christopher T. Su Veena Shankaran Source Type: research
Molecular tumour boards — current and future considerations for precision oncology
Nature Reviews Clinical Oncology, Published online: 16 October 2023; doi:10.1038/s41571-023-00824-4According to the precision oncology paradigm, cancer therapies are increasingly being matched to specific sensitizing alterations using a biomarker-directed approach. However, the criteria for determining the actionability of molecular alterations and selecting matched treatments evolve over time. Molecular tumour boards (MTBs) have emerged as means to capitalize on the collective knowledge of various experts to interpret molecular-profiling data and to eliminate subjectivity in treatment selection. This Review describes the ...
Source: Nature Reviews Clinical Oncology - October 16, 2023 Category: Cancer & Oncology Authors: Apostolia M. Tsimberidou Michael Kahle Henry Hiep Vo Mehmet A. Baysal Amber Johnson Funda Meric-Bernstam Source Type: research
Dose-reduction trials in oncology — aiming for less toxicity and better quality of life at lower costs
Nature Reviews Clinical Oncology, Published online: 16 October 2023; doi:10.1038/s41571-023-00831-5Projected increases of cancer-attributable health-care costs, accompanied by staff shortages, will impose future economic and operational challenges on national health-care systems. Herein, we highlight a series of clinical and health economic rationales in support of publicly funded clinical trial teams that conduct real-world dose-reduction trials aiming for adjustment of cancer drug label doses to reduce not only the financial burden on payers, but also the toxicity burden on patients. (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 16, 2023 Category: Cancer & Oncology Authors: Kim Theilgaard-M önch Lars Holger Ehlers Source Type: research
Progression-free survival, disease-free survival and other composite end points in oncology: improved reporting is needed
Nature Reviews Clinical Oncology, Published online: 12 October 2023; doi:10.1038/s41571-023-00823-5The use of composite end points in clinical trials can expedite drug development and approval, and thus improve patient access to novel treatments, but are often vaguely and heterogeneously defined, with considerable inter-study variation in the component events that are included. The different component events can vary in clinical significance and be differentially affected by treatment but, nevertheless, are rarely reported separately. In this Perspective, Walia et al. define composite outcomes that are commonly used in onc...
Source: Nature Reviews Clinical Oncology - October 12, 2023 Category: Cancer & Oncology Authors: Anushka Walia Jordan Tuia Vinay Prasad Source Type: research
Dabrafenib–trametinib moves to the first line in low-grade glioma
Nature Reviews Clinical Oncology, Published online: 10 October 2023; doi:10.1038/s41571-023-00829-zDabrafenib–trametinib moves to the first line in low-grade glioma (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 10, 2023 Category: Cancer & Oncology Authors: Diana Romero Source Type: research
Irradiation of asymptomatic bone metastases improves outcomes
Nature Reviews Clinical Oncology, Published online: 06 October 2023; doi:10.1038/s41571-023-00828-0Irradiation of asymptomatic bone metastases improves outcomes (Source: Nature Reviews Clinical Oncology)
Source: Nature Reviews Clinical Oncology - October 6, 2023 Category: Cancer & Oncology Authors: David Killock Source Type: research
